In support of these findings, Ishibashi et al. [14] reported that three years of SGLT-2 inhibitor therapy in patients with modestly controlled type 2 diabetes significantly improved neuropathy outcomes and decelerated nephropathy progression. The gene discussed is SLC5A2; the disease is neuropathy.